Your browser doesn't support javascript.
loading
A First-in-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination with Erlotinib in Advanced Cancer.
Rosen, Lee S; Goldman, Jonathan W; Algazi, Alain P; Turner, P Kellie; Moser, Brian; Hu, Tianle; Wang, Xuejing Aimee; Tuttle, Jay; Wacheck, Volker; Wooldridge, James E; Banck, Michaela.
Afiliação
  • Rosen LS; Department of Medicine, University of California, Los Angeles, California. lrosen@mednet.ucla.edu.
  • Goldman JW; Department of Medicine, University of California, Los Angeles, California.
  • Algazi AP; Department of Medicine, University of California, San Francisco, California.
  • Turner PK; Eli Lilly and Company, Indianapolis, Indiana.
  • Moser B; Eli Lilly and Company, Indianapolis, Indiana.
  • Hu T; Eli Lilly and Company, Indianapolis, Indiana.
  • Wang XA; Eli Lilly and Company, Indianapolis, Indiana.
  • Tuttle J; Eli Lilly and Company, Indianapolis, Indiana.
  • Wacheck V; Eli Lilly Regional Operations GmbH, Vienna, Austria.
  • Wooldridge JE; Eli Lilly and Company, Indianapolis, Indiana.
  • Banck M; Mayo Clinic Rochester, Rochester, Minnesota.
Clin Cancer Res ; 23(8): 1910-1919, 2017 04 15.
Article em En | MEDLINE | ID: mdl-27803065

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Anticorpos Monoclonais Humanizados / Cloridrato de Erlotinib / Neoplasias / Antineoplásicos Tipo de estudo: Clinical_trials Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Anticorpos Monoclonais Humanizados / Cloridrato de Erlotinib / Neoplasias / Antineoplásicos Tipo de estudo: Clinical_trials Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article